Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Authors: Alison M. Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar, Allan J.W. Lui, Morana Vojnic, Sara H. Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N. O'Connor, Cecile A.W. Geuijen, Ron C.J. Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M. O'Reilly, Marc Ladanyi, Alexander Drilon, Romel Somwar
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362556110